Compare ZYME & EFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZYME | EFC |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2022 | 2007 |
| Metric | ZYME | EFC |
|---|---|---|
| Price | $26.56 | $12.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | ★ $38.90 | $14.55 |
| AVG Volume (30 Days) | 514.3K | ★ 1.1M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 11.84% |
| EPS Growth | ★ 33.33 | N/A |
| EPS | N/A | ★ 1.21 |
| Revenue | ★ $105,965,000.00 | N/A |
| Revenue This Year | $183.10 | N/A |
| Revenue Next Year | N/A | $43.05 |
| P/E Ratio | ★ N/A | $10.22 |
| Revenue Growth | ★ 38.87 | N/A |
| 52 Week Low | $16.00 | $11.28 |
| 52 Week High | $31.34 | $14.12 |
| Indicator | ZYME | EFC |
|---|---|---|
| Relative Strength Index (RSI) | 47.51 | 30.64 |
| Support Level | $22.10 | $12.37 |
| Resistance Level | $27.30 | $13.76 |
| Average True Range (ATR) | 0.99 | 0.21 |
| MACD | -0.19 | -0.05 |
| Stochastic Oscillator | 24.20 | 16.19 |
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Ellington Financial Inc is a specialty finance company. Its primary investment objective is to generate attractive, risk-adjusted total returns for its shareholders by making investments. The company has two reportable segments; The Investment Portfolio Segment is focused on investing in a diverse array of financial assets, including residential and commercial mortgage loans, residential mortgage-backed securities, non-mortgage- and mortgage-related derivatives, debt and equity investments in loan origination companies, and other strategic investments, and The Longbridge Segment is focused on the origination and servicing of reverse mortgage loans. It acquires reverse mortgage loans both through its origination activities and through secondary market purchases.